Moderna share price soars 90% on melanoma vaccine trial success

President Donald Trump has a good claim, rhetorically at least, to one of the technologies that his own movement sometimes loves to hate.

Shares of Moderna soared as much as 90% in premarket trading Wednesday, pacing what would become the biotech company's best trading session on record, after the company and partner Merck announced that their experimental personalized mRNA cancer vaccine succeeded in a large, late-stage clinical trial for melanoma.

Optimism about a potential breakthrough in personalised cancer treatment has sent shares in Moderna soaring by nearly 100%.

More than 8,500 Americans are expected to die of melanoma this year